HER2

20 registered clinical trials studyying HER2 — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology NCT07454941	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	—
Not Yet Recruiting	Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy NCT06828588	Vanderbilt-Ingram Cancer Center	EARLY_Phase 1
Not Yet Recruiting	MA-CRC-II-016 SHR-1811 NCT07355764	Peking Union Medical College Hospital	Phase 2
Recruiting	A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562	Cogent Biosciences, Inc.	Phase 1
Recruiting	Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management NCT07356544	Gruppo Oncologico Italiano di Ricerca Clinica	—
Recruiting	Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresect NCT07506057	Xiujuan Qu	Phase 2
Recruiting	Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Lin NCT07285941	Zhejiang Cancer Hospital	Phase 2
Recruiting	A Composite Assay for HER2-positive Early-stage Breast Cancer Management NCT06762977	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	—
Active Not Recruiting	Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliar NCT06178445	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Recruiting	A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871	Iambic Therapeutics, Inc	Phase 1
Completed	HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic NCT06125314	AstraZeneca	—
Recruiting	RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	—
Recruiting	RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Exp NCT05957757	RenJi Hospital	Phase 2
Active Not Recruiting	Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression NCT05661357	Zhongnan Hospital	Phase 4
Unknown	Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy NCT05649163	Shen Lin	—
Unknown	Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System NCT03185988	Shen Lin	Phase 2
Completed	Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China NCT03437837	Peking University First Hospital	—
Terminated	A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With NCT02202746	Clovis Oncology, Inc.	Phase 2
Completed	Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer NCT04249440	Zhejiang Cancer Hospital	—
Completed	PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer NCT01152853	Seoul National University Hospital	Phase 2